Why Theravance Biopharma Stock Dived 16% Today

why theravance biopharma stock dived 16 today

Sumary of Why Theravance Biopharma Stock Dived 16% Today:

  • So what This morning, Theravance divulged the top-line results from its phase 3 study of Ampreloxetine, a drug aimed at treating symptomatic neurogenic orthostatic hypotension (nOH, essentially a disorder in which the body does not effectively regulate blood pressure).
  • This was particularly disappointing given that a 2018 phase 2 study showed positive top-line results for Ampreloxetine.
  • The news comes less than a month after the biotech company’s drug for inflammatory bowel disease, izencitinib, flopped in a phase 2 trial.
  • Which, in turn, was two months after its COVID-19 pipeline drug nezulcitinib fell short in phase 2 testing.

Want to know more click here go to source.

From -

Generic selectors
Exact matches only
Search in title
Search in content

Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.